H.B. 30 Summary

• Establishes penalties on prescription drug manufacturers with at least $250,000 in annual sales in Hawaii for "unsupported price increases" not backed by new clinical evidence

• Penalty equals 80% of the revenue difference between actual sales and what sales would have been if the manufacturer maintained the prior year's wholesale acquisition cost adjusted for inflation

• Prohibits manufacturers of identified drugs from withdrawing those drugs from Hawaii to avoid penalties and requires 180-day advance notice before withdrawal; violations subject to $500,000 penalty

• Creates the "identified drug offset special fund" to deposit collected penalties and use funds primarily to offset consumer out-of-pocket costs for identified drugs, with limited use for administrative expenses

• Requires the insurance commissioner to use the Institute for Clinical and Economic Review's annual Unsupported Price Increase Report to identify covered drugs and notify manufacturers within 60 days of publication; provides for appeals and judicial review through circuit court